Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Colon; Signet Ring Adenocarcinoma of the Rectum; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
Intervention: fluorouracil (Drug); sodium phenylbutyrate (Drug); indomethacin (Drug); recombinant interferon gamma (Biological)
Phase: Phase 1/Phase 2
Status: Terminated
Sponsored by: National Cancer Institute (NCI) Official(s) and/or principal investigator(s): Max Sung, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai
Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the
growth of the tumor. Combining more than one drug with interferon-gamma may kill more tumor
cells. This phase I/II trial is studying the side effects and best dose of giving
fluorouracil together with phenylbutyrate, indomethacin, and interferon-gamma and to see how
well it works in treating patients with stage IV colorectal cancer
Clinical Details
Official title: Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Toxicity of flurouracil (FU) when given in escalating doses in combination with fixed doses of phenlylbutyrate (PB), indomethacin and recombinant human interferon-gamma (rhIFNg) to patients with advanced colorectal cancer (Phase I)Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)
Detailed description:
PRIMARY OBJECTIVES:
I. To determine in a Phase I study the toxicity of flurouracil (FU) when given in escalating
doses in combination with fixed doses of phenlylbutyrate (PB), indomethacin and recombinant
human interferon-gamma (rhIFNg) to patients with advanced colorectal cancer.
II. To determine in a Phase II study the efficacy of FU in combination with PB, indomethacin
and rhIFNg in patients with advanced colorectal cancer.
OUTLINE: This is a dose-escalation study of fluorouracil (5-FU).
Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours
and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4,
and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients
experience dose-limiting toxicity (DLT).
Phase II :Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in
phase I at the MTD.
Patients are followed for survival.
PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for the phase I portion of this
study and approximately 46 patients will be accrued for the phase II portion of this study.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stage IV colorectal adenocarcinoma, excluding brain metastases
- Histological confirmation of colorectal adenocarcinoma
- Previously untreated patients
- Previously treated patients
- For the Phase I trial, no limitations
- For the Phase II trial, previous treated limited to adjuvant radiation and/or
chemotherapy which is completed at least 12 months before documentation of
metastatic disease; patients may not have received chemotherapy for metastatic
disease
- For the Phase I trial, patients may have measurable disease or unmeasurable disease;
for the Phase II trial, patients must have measurable disease in at least two
dimensions on x-rays, CT scan or MRI
- Expected survival of at least 16 weeks
- Performance status of >= 70% (Karnofsky)
- WBC >= 3000 uL
- Platelet count >= 100,000/uL
- Bilirubin =< 2 x ULN
- Creatinine =< 2 x ULN
- Not pregnant and not lactating; women of child bearing age must have negative
pregnancy test (beta-hcg)
- No allergies to interferon-gamma or E. coli derived products
- No serious medical intercurrent medical illnesses, including Class III or IV
cardiovascular disease; patient may not be dependent on immunosuppressive drugs
including corticosteroids, and may not receive these drugs for the entire duration of
the study
- No diarrhea, and with adequate oral intake
- Patients of child-bearing age and potential must agree to use adequate birth control
other than oral contraceptives for the entire duration of the study
- No previous or concurrent malignancy except inactive nonmelanoma skin cancer, in situ
carcinoma of the cervix, grade 1 bladder cancer, or other cancers if the patient has
been disease free for >= 5 years
- Patients must be oriented and rational, and aware of the investigational nature of
the study
Locations and Contacts
Mount Sinai Medical Center, New York, New York 10029, United States
Additional Information
Starting date: May 1997
Last updated: January 31, 2013
|